Compare LRE & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | LRE | PPCB |
|---|---|---|
| Founded | 2001 | 2007 |
| Country | Japan | Australia |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.5M | 20.4M |
| IPO Year | 2023 | N/A |
| Metric | LRE | PPCB |
|---|---|---|
| Price | $1.30 | $0.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.5K | ★ 266.9K |
| Earning Date | 01-01-0001 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.27 | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $130,601,512.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.04 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $0.73 |
| 52 Week High | $2.97 | $145.46 |
| Indicator | LRE | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 51.21 | N/A |
| Support Level | $1.25 | N/A |
| Resistance Level | $1.29 | N/A |
| Average True Range (ATR) | 0.06 | 0.00 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 100.00 | 0.00 |
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.